Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

3.480 -0.030 (-0.85%)
Streaming Delayed Price Updated: 10:26 AM EDT, Aug 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NRX Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
FDA First Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies Noted for Suicidal Bipolar Depression Treatment from NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
Conference Call 8:30 a.m. ET, Monday, August 10, 2026 
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
First Patients Treated via FDA-Cleared Transcranial Magnetic Stimulation, Plus FDA Grant on D-Cycloserine-Based Drug for Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Government
News headline image
New to The Street Announces Broadcast of Show #759 on Bloomberg Television Across the U.S., MENA and Latin America tonight 630pm est.
From New to The Street
Via ACCESS Newswire
News headline image
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA
From New to The Street
Via ACCESS Newswire
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option
Offering was led by B Group Capital with significant participation from, among others, Columbia Threadneedle Investments, Corbets Capital, Venture 76, and Mossrock Capital 
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
First Commercial Deployment of FDA-Cleared Transcranial Magnetic Stimulation (TMS) for Major Depressive Disorder and Other Neurological Conditions: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Government
News headline image
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medicus Pharma
Via ACCESS Newswire
News headline image
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Clearance for Depression and Suicidality Trial
Via Investor Brand Network
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
NetworkNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Initiates First Commercial Manufacturing Order For Preservative-Free Ketamine
Via Investor Brand Network
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
GLOBAL MARKETS SPOTLIGHT: New to The Street Show #748 Delivers High-Impact CEO Interviews and Spotlight TV Commercials Across Bloomberg to 250M+ Households Worldwide
Via ACCESS Newswire
News headline image
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global
Via ACCESS Newswire
News headline image
Positive FDA Response on Preservative-Free Ketamine After President Trump Orders Accelerated Approval for Psychedelic Medication Developers Including NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Government
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives Positive FDA Review Letter Supporting Ketamine ANDA Progress
Via Investor Brand Network
News headline image
NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Presidential Executive Order to Accelerate Approval of Psychedelic Medications; Those Being Developed by NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Government
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.